Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study

Clinical Therapeutics

Volumn 39, Issue 6, 2017, Pages 1146-1160

  Wang, Feng ^a   Mishina, Sari ^a   Takai, Shinji ^b   Le, T Kim ^a   Ochi, Kenya ^b   Funato, Kotaro ^a   Matsuoka, Shozo ^b   Ohe, Yuichiro ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b ONO PHARMACEUTICAL CO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Japan; non small cell lung cancer; real world data; retrospective study

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; CRIZOTINIB; DOCETAXEL; ERLOTINIB; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SEX RATIO; SQUAMOUS CELL LUNG CARCINOMA; SYSTEMIC THERAPY; TREATMENT DURATION; FACTUAL DATABASE; LUNG TUMOR; MIDDLE AGED; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; YOUNG ADULT;

EID: 85019359360     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.04.010     Document Type: Article

References (17)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan. Projected Cancer Statistics, 2015. http://ganjoho.jp/en/public/statistics/short_pred.html. Updated May 26, 2015. Accessed June 16, 2016.
2. Ferlay, J., Soerjomataram, I., Ervik, M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France http://globocan.iarc.fr Accessed June 3, 2016.
3. Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N Engl J Med 359 (2008), 1367–1380.
4. Gandara, D.R., Lara, P.N. Jr, Mack, P., et al. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 10 (2009), 148–150.
5. Morgensztern, D., Ng, S.H., Gao, F., et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5 (2010), 29–33.
6. Scagliotti, G.V., Bironzo, P., Vansteenkiste, J.F., Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treat Rev 41 (2015), 465–475.
7. The Japan Lung Cancer Society. Japan Guidelines of Lung Cancer Therapy. 2015 ed. [Internet]. Japan: Kanehara Shuppan 2015. http://www.haigan.gr.jp/modules/guideline/index.php?content_id=3. Accessed June 3, 2016.
8. Kuwabara, K., Matsuda, S., Fushimi, K., et al. Differences in practice patterns and costs between small cell and non-small cell lung cancer patients in Japan. Tohoku J Exp Med 217 (2009), 29–35.
9. Penrod J.R., Korytowsky B, Petrilla A, et al. Survival of US Medicare patients with advanced non-small cell lung cancer (NSCLC) by line of therapy. Poster presented at: American Society of Clinical Oncology; May 30–June 3, 2014; Chicago, IL.
10. Orsini LS, Korytowsky B, Petrilla A, et al. Real-world use of systemic anti-cancer treatment by histology and line of therapy (LOT) in US Medicare patients with advanced non-small cell lung cancer (NSCLC). Poster presented at: Chicago Multidisciplinary Symposium on Thoracic Oncology; October 30–November 1, 2014; Chicago, IL.
11. Davis, K.L., Goyal, R.K., Able, S.L., et al. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer 87 (2015), 176–185.
12. Sacher, A.G., Le, L.W., Lau, A., et al. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. Cancer 121 (2015), 2562–2569.
13. Noonan, K., Tong, K.M., Laskin, J., et al. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort. Lung Cancer 86 (2014), 344–349.
14. Sacher, A.G., Le, L.W., Lau, A., et al. Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents. J Clin Oncol. (Abstract Supplement), 2012, A7606.
15. Annemans, L., Aristides, M., Kubin, M., Real-life data: a growing need. ISPOR Connections 13 (2007), 8–12 https://www.ispor.org/News/articles/Oct07/RLD.asp Accessed December 6, 2016.
16. Shi, Y., Au, J.S., Thongprasert, S., et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9 (2014), 154–162.
17. Salloum, R.G., Smith, T.G., Jensen, G.A., et al. Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. Lung Cancer 75 (2012), 255–260.